Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.62 |
| ▸ | NPY1R | P25929 | 8/20 | 0.62 |
| ▸ | NPY2R | P49146 | 6/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.62 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymopentin SCHEMBL29512397 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| Thymopentin SCHEMBL44001 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| Thymopentin SCHEMBL7498758 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| Thymopentin SCHEMBL29512388 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| Thymopentin SCHEMBL29512423 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30331711 | 1.00 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| Thymopentin SCHEMBL270731 | 0.98 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL29611531 | 0.98 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL29512422 | 0.96 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30918783 | 0.95 | NPY4R (0.69) | NPY4RNPY1RNPY2RNPY5RIL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1714861-B | Thymus penta peptide slow releasing micro ball and its preparing method | INST MATERIA MEDICA CAMS | 2012-10-10 | — | — | CN | claimed |
| CN-109836455-B | Liquid phase synthesis method of thymopentin based on phosphorus or phosphorus acyloxy diphenyl methanol and derivatives thereof and assistance | 西北工业大学 | 2021-11-16 | — | — | CN | disclosed |
| CN-105125451-A | Composition capable of inhibiting hair growth and preparation method thereof | LIN TONG | 2015-12-09 | — | — | CN | disclosed |
| CN-105106932-A | Hair regrowth composition and preparation method thereof | LIN TONG | 2015-12-02 | — | — | CN | disclosed |
| CN-103536898-B | Thymopentin (TP-5) drug composition | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2015-06-17 | — | — | CN | disclosed |
| CN-103536567-B | Thymopentin (TP-5) powder injection | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8822542-B2 | Isoketal scavengers and mitigation of disorders involving oxidative injury | VANDERBILT UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103536567-A | Thymopentin (TP-5) powder injection | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| CN-103536898-A | Thymopentin (TP-5) drug composition | CHENGDU TIANTAISHAN PHARMACEUTICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| EP-2477594-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | Vanderbilt University (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | VANDERBILT UNIVERSITY | 2012-06-21 | — | — | US | disclosed |
| WO-2011008202-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | VANDERBILT UNIVERSITY (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7705054-B1 | Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases | VANDERBILT UNIVERSITY (US) | 2010-04-27 | — | — | US | disclosed |
| US-6677161-B2 | Aerogels and other coatings as collection media and matrix supports for MALDI-MS applications | VERIDIAN ERIM INTERNATIONAL, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20020081746-A1 | Aerogels and other coatings as collection media and matrix supports for MALDI-MS applications | VERIDIAN ERIM INTERNATIONAL, INC. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157501-A1 | ISOKETAL SCAVENGERS AND MITIGATION OF DISORDERS INVOLVING OXIDATIVE INJURY | PDXK, KYNU, FN3K | NPY4R 964/4885NPY1R 1244/4885NPY2R 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.